Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03666065 · ClinicalTrials.gov registry record · Early Phase 1
Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients
A Early Phase 1 study of Type 1 Diabetes, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT03666065: Completed Early Phase 1 study of Type 1 Diabetes, sponsored by Yale University.
NCT03666065 is a Early Phase 1 study of Type 1 Diabetes that has completed, run by Yale University. The registered enrollment target is 3 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03666065, a Early Phase 1 study of Type 1 Diabetes, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to compare the pharmacokinetic (PK) profile of diluted insulin aspart (U25) with undiluted insulin aspart (U100) in school-aged children and adolescents with type 1 diabetes (T1D) utilizing the euglycemic clamp technique and a standardized meal in a controlled research environment. The investigators hypothesize that dilution of insulin aspart (U25) will alter the PK properties as compared to undiluted aspart.
Primary Outcome
maximum insulin concentration
Conditions Studied
Interventions
- DRUG Aspart insulin
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2023-06-30 |
| Phase | Early Phase 1 |
What the finished NCT03666065 record still lists
NCT03666065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Aspart insulin is the first listed.
NCT03666065 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03666065 about?
NCT03666065 is a clinical study titled "Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients". The aim of this study is to compare the pharmacokinetic (PK) profile of diluted insulin aspart (U25) with undiluted insulin aspart (U100) in school-aged children and adolescents with type 1 diabetes (T1D) utilizing the euglycemic clamp technique and a standardized meal in a controlled research envir...
What is the current status of trial NCT03666065?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2020-01-01. Estimated completion is 2023-06-30.
What conditions does trial NCT03666065 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT03666065?
The interventions under investigation include: Aspart insulin (DRUG).
Who is sponsoring clinical trial NCT03666065?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03666065 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03666065's enrollment target sits among peer trials
3 199th of 198 the lowest of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
RECRUITING · Early Phase 1
-
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
RECRUITING · Early Phase 1
-
Effect of C-peptide on Hypoglycemic Counterregulation
RECRUITING · Early Phase 1
-
Adrenergic System in Islet Transplantation
ACTIVE NOT RECRUITING · Early Phase 1
-
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
COMPLETED · Early Phase 1
-
Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI